Novavax shares fall for second day; EMA decision on its COVID shot expected in Oct

Genprex

21/09/2023 16:58

** Shares of Novavax  NVAX.O  fall 2.57% to $6.87, in a
second straight session
    ** European Medicines Agency director Emer Cooke said the
agency expects to make a decision on co's updated COVID vaccine
in October
    ** The agency began its evaluation on Aug. 24 and the
vaccine was still under review
    ** The shot is also under review by the U.S. FDA
    ** NVAX shares have fallen ~12% since FDA authorized the use
of vaccines from rivals Pfizer  PFE.N /BioNTech  22UAy.DE   and
Moderna  MRNA.O  
    ** Stock down ~33% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))